ENDEAVOR IS A CLINICAL STAGE COMPANY FOCUSED ON DEVELOPING DRUGS THAT TARGET THE CAUSE OF LIFE-THREATENING DISEASES
Location: United States, California, San Diego
Employees: 11-50
Total raised: $295.5M
Founded date: 2018
Investors 4
| Date | Name | Website |
| 04.05.2022 | Crescent E... | crescenten... |
| - | Omega Fund... | omegafunds... |
| 23.01.2021 | Longitude ... | longitudec... |
| 16.08.2024 | SymBiosis | symbiosis.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 24.04.2024 | Series C | $132.5M | - |
| 08.02.2022 | Series B | $101M | - |
| 07.01.2021 | Series A | $62M | - |
Mentions in press and media 14
| Date | Title | Description |
| 25.04.2024 | Endeavor BioMedicines Secures $132.5M for Medical Breakthroughs | San Diego's Endeavor BioMedicines has clinched a hefty $132.5M in Series C financing, spearheaded by AyurMaya and a lineup of heavyweight investors. This injection of funds will propel the clinical development of ENV-101, targeting fibrotic... |
| 24.04.2024 | Endeavor BioMedicines Gets $132.5M | San Diego-based biotechnology company Endeavor BioMedicine said this morning that it has raised $132.5M in the company's Series C financing. The company said the funding was led by AyurMaya, an affiliate of Matrix Capital Management, plus n... |
| 24.04.2024 | Endeavor BioMedicines Raises $132.5M in Series C Financing | Endeavor BioMedicines, Inc., a San Diego, CA-based clinical-stage biotechnology company, closed a $132.5m Series C financing, including the conversion of a $5m convertible instrument. The round was led by AyurMaya, an affiliate of Matrix Ca... |
| 19.10.2023 | Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC) | Endeavor obtains exclusive worldwide rights to Hummingbird Bioscience's anti-HER3 ADC to be developed for patients with HER3-expressing tumors Hummingbird Bioscience to receive upfront and milestone payments up to $430 million, plus royalti... |
| 08.02.2022 | Endeavor BioMedicines garners $101M from a Series B funding round to advance pipeline programs | - |
| 08.02.2022 | San Diego’s Endeavor BioMedicines nets $101M to hunt down genetic culprits of cancer | Endeavor BioMedicines, a precision therapy startup targeting the root drivers of cancer and other ailments, has raised $101 million in a second round of venture capital financing. The money will be used to advance certain therapies in San D... |
| 08.02.2022 | Endeavor BioMedicines Gains $101M More For Precision Medicine | San Diego-based Endeavor BioMedicines, a clinical-stage biotechnology company focused on oncology and fibrosis, says it has raised $101M in its Series B funding round. The funding was led by Ally Bridge Group and Avidity Partners, and also ... |
| 07.02.2022 | Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline | Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the completion of a $101 million Series B financing, led by Ally Bridge Group and... |
| 07.02.2022 | Endeavor snags $101M to go after Boehringer, Roche in lung scarring—and do some asset shopping | Endeavor Biomedicines wants to best the two idiopathic pulmonary fibrosis (IPF) drugs on the market by going after the so-called Hedgehog pathway—what it calls the "root cause" of the disease—and now it has $101 million in new fun... |
| 07.02.2022 | Endeavor snags $101M to go after Boehringer, Roche in lung scarring—and do some asset shopping | Endeavor Biomedicines wants to best the two idiopathic pulmonary fibrosis (IPF) drugs on the market by going after the so-called Hedgehog pathway—what it calls the "root cause" of the disease—and now it has $101 million in new fun... |
Show more